Q1 2023 Pfizer Inc Earnings Call
Okay.
Good day, everyone and welcome to Pfizer's first quarter 2023 earnings conference call.
Today's call is being recorded.
At this time I would like to turn the call over to Mr. Chris <unk> Senior Vice President and Chief Investor Relations Officer. Please go ahead Sir.
Thank you Chelsea good morning, everyone welcome to Pfizer's first quarter earnings call I'm joined today by Dr. Albert boiler, our chairman and CEO .
We've done it in our CFO .
Michael Johnson President of worldwide research and development in medical.
Joining for the Q&A session. We will also have Angela Wong Chief commercial officer, and President Global biopharmaceutical business.
Malik our chief business Innovation Officer, Dr. William Powell, our Chief Development Officer, and Doug length, or our general counsel.
Before we begin the call I want to remind you of some logistical items.
The materials for this call another earnings related materials on the Investor Relations section of Pfizer Dot com.
Please see our forward looking statements disclaimer on slide three.
Additional information regarding these statements and our non-GAAP financial measures is available in our earnings release and our SEC.
<unk> Form 10-K, and 10-Q under risk factors and forward looking information and factors that may affect future results.
Forward looking statements on the call are subject to substantial risks and uncertainties.
Only as of the calls original date.
We undertake no obligation to update or revise any of these statements with that I'll turn the call over to Albert. Thank you, Chris Hello, everyone and thank you for joining us today.
Q1 was a solid foundational quarter and what do you expect to be an exciting year for Pfizer in patients.
Our financial results were as we anticipate.
Non corporate revenues grew 5% operationally compared with a year ago walk there.
While overall revenues declined 26% operationally, primarily who had previously communicated and expected decline in Maryland I think.
But I think.
Even with this decline our corporate franchises remain significant contributors to the business with a combined seven 1 billion in revenues during the quarter.
This growth was driven primarily by a recently acquired products and architect for migraine Amdocs bright definitely sickle cell disease or anti Infectives comparison.
And then on wallboard are obviously up relation indication in the U S and our Greentech the assembly of products for the treatment of trustee or amyloid cardiomyopathy.
We also continue to be proud of our pace I mean.
During the first quarter of more than 250 million patients what do they do with our medicines and vaccines.
With this solid start to the year.
They try to grow while non coffee its revenues by seven 9% up Directionally in 2023.
That's because the majority of our potential product launches as you can see mop on this slide are expected to occur in the second half of the year following regulatory approvals were not yet secured.
As such we expect our non coffee to revenues to grow at a faster rate in the second half of the year.
Overall, we are in the meats or an 18 month period, which we expect to launch up to 19 forecast, you'll see products and indications.
Over the first four months of a year, we have made excellent progress towards these goals with the approval of a disaster right.
An expanded indication for <unk> to include the lessons and last week's approval of a trend worth waiting for pediatric use all in the U S.
We also have secured a regulatory filing acceptances for I don't know that that up.
Dolby and Mcdonald before non small cell lung cancer and for all RSV maternal vaccine candidate, which if approved would be the first vaccine for administration to pregnant with individuals.
To protect against the complications of RSV disease in infants from birth through six months.
In addition, the U S food and drug administration.
Because granted priority.
And the European Medicines agency.
Our MAA filing for review of consumer for use in combination with extended for patients with newly diagnosed metastatic castration resistant prostate cancer based on the dollar broke to results.
Regarding our COVID-19 franchise, we continue to expect 2020, so it will be a transitional year as the virus continues to mutate and we moved from advanced purchases under the government contracts to more of a transitional supply arrangement and the commercial model for bulk commandment.
Globally in the U S.
Previously discussed in 2023, and 2024, we expect vaccine utilization to decline compared with 2022 VAT.
Starting in 2025 and continued in 2026 and beyond we expect to see an increase in COVID-19 vaccination rates, assuming the successful development and approval of various COVID-19 combination vaccines.
Outside the U S. We expect these general trends to be similar with some variations from country to country.
Regarding park slope, we continue to expect the government inventory that was built around the world last year could be absorbed by the end of this year.
We then expect but yesterday before and be young the courses sold.
And of course, its use will more closely align.
With its robust efficacy consistent safety profile and potential to mitigate the burden of COVID-19 on patients and their families co system and society exploring is proving to be an important endurable complimentary to oxy Mason strategies or the estimated 40% of the global adult population at high risk.
For progression to severe disease.
Yeah.
Now, let's take a look at size US next book that selling themselves.
Button again.
Oncology remains a core therapeutic area for Pfizer and we believe the proposed acquisition of <unk> will enhance our position in this important space.
The graphs on planning is already underway and we continue to expect the deal to close in late 2023 for early 'twenty 'twenty four subject, sorry, Oh gosh somebody closing conditions.
By combining sitos category, leading antibody drug conjugate technology with Pfizer's scale.
Expertise and capabilities, we believe we can accelerate potential breakthroughs in cancer medicines and introduce new solutions to patients around the world.
Yeah.
The potential combined commercial infrastructure for Pfizer It seems that it would be three times the size of Alco season alone in the U S and four five times larger globally.
As a result, we believe acquiring <unk> could contribute more than 10 billion in 'twenty started your risk adjusted returns.
Potential significant growth beyond 'twenty.
Even with this season, given the strength of our balance sheet and cash flows we continue to have the flexibility to take this.
All actions to create shareholder value.
David will provide more details on this during this presentation.
One of the key areas of focus for Pfizer in 2020, Three's continuing to build trust, which is a key asset for everybody biopharmaceutical company.
Since the beginning of the year.
We have received two accolades that demonstrate we are doing just that.
February Pfizer was named to the top 10 of Forbes as most admired companies for the second year in at all.
Pfizer has one of the world's most ethical companies also for the second year in general.
It's Pfizer thrush everything it gives us our license allows.
It allows us to attract the best talent and enables us to deliver breakthroughs that change patients' lives.
Got it.
Over to date.
So David Michael will provide an update on R&D pipeline.
Thank you Albert and good morning, everyone I want to begin with Pfizer's capital allocation strategy before we dive into additional commentary about our quarterly performance and importantly, our outlook for the remainder of 2023.
As you know our strategy strategy includes three main pillars, we investing in our business growing and paying dividends and repurchasing our shares.
In the first three months of 2023, we've invested $2 $5 billion in internal R&D.
And returned $2 $3 billion to shareholders via our quarterly dividend.
And importantly allocated approximately $43 billion for the proposed <unk> acquisition.
Over the last few years, we invested heavily into our business to drive long term growth and enhance long term shareholder value.
We've invested in Pfizer's own science, while acquiring the best external science to supplement our pipeline.
Since 2022 we've invested approximately $70 billion, including sea Gen and business development.
In addition, we have continued to grow our dividend.
For the past 14 years, we have raised our dividend annually since 2010, our quarterly cash dividend grew from 16 cents a share to <unk> 41, a share in 2023.
Looking ahead as we exit this unprecedented period of anticipated launches, we would expect to achieve operating margin improvement over time.
As we began to deliver delever our capital structure. After the closing of the <unk> transaction, we expect to return to a more balanced capital allocation mix between our three pillars why would why we will continue to invest in our business. We do expect more balance between that probably.
Already and returning value to our shareholders via increased dividends and value enhancing share repurchases.
Our capital allocation strategy is squarely folks focused on driving shareholder value.
At the same time remaining committed to our high investment grade tier one commercial paper rating.
Now turning to the quarter as Albert said, our results were in line with Rx base expectations, albeit slightly better than consensus.
As expected overall revenues declined 26% operationally.
Really driven by the anticipated decline in commodity which was partially offset by strong <unk> sales.
I want to point out that our COVID-19 products produced $7 $1 billion in revenues in the first quarter alone.
Our non COVID-19 operational revenues.
It was solid at 5% year over year.
Primarily driving this growth was the inclusion of <unk> ODT and ox Friday.
And an increase in <unk> revenues in China.
Revenues for Alex Western U S and the Vindical family globally also contributed to this growth.
Now I want to remind you of the seasonality of some of our products in the first quarter Nortek ODT and ox bright it typically have lower sales quarter on quarter due to annual co pay reset dynamics with higher sales statistic anticipated in latter quarters.
Most importantly, both products continue to experience strong growth in demand.
So Paulo, So Paulo, Zhan revenues increased more than $100 million year over year due to higher demand in China during the quarter, which we do not expect to be sustained going forward.
The demand was due to increased bacterial infection from patients being hospitalized for COVID-19.
To help ensure the success of the expected launches a large number of new and acquired products and indications we've increased our investments in S. A N a.
Investments are squarely focused on Pfizer's 2025 to 2030 growth aspirations.
Now moving to the bottom line reported diluted earnings per share this quarter declined by 29% to 97 cents a share while adjusted diluted earnings per share of $1 23 declined 20% on an operational basis during the quarter.
Once again this quarter foreign exchange movements significantly impacted our results, reducing first quarter revenues by $730 million or 3% and.
And adjusted diluted earnings per share by seven.
Or 4% compared to L y.
Now turning to the full year financial outlook for the company our full year 2023 guidance remains unchanged.
Total company basis, we continue to expect revenues of $67 billion to $71 billion, reflecting an operational decline of 31% at the midpoint.
With 5% operational growth in our non Covid revenues. This quarter, we are on track to achieve our non COVID-19 revenue guidance of 7% to 9% operational growth for the full year.
Given that a large number of launches are expected to incur in the third and fourth quarter of 'twenty. Three we anticipate our quarterly revenues will not be linear this year and that our non COVID-19 revenues will grow more quickly in the back half of this year versus the first half of 'twenty three.
In terms of our cobot products commodity impacts slow, but we expect sales to trend where seasonally this year.
Given these dynamics, we expect significantly lower sales contributions from our COVID-19 products in the second quarter versus the first quarter.
In fact, given the anticipated timing of approvals for our fall vaccine was strained change we would expect more substantial vaccine deliveries to start in September which is late in the U S third quarter and the beginning of our international fourth quarter.
With respect to <unk>, we continue to expect 23 to be a transitional year as we anticipate shifting into a commercial market in the second half of this year.
We are reaffirming our adjusted diluted earnings per share guidance range of $3.25 to $3 45 per share.
On a full year basis, we expect that foreign exchange will have an unfavorable impact compared with full year 2022 of approximately 13 cents on adjusted diluted earnings per share.
We are also reaffirming the remaining components of our full year 2023 guidance, which you can find in the appendix of the Q1 'twenty three earnings presentation.
So in closing this is an exciting period for Pfizer as we continue to invest to drive long term growth and importantly, enhanced long term shareholder value.
Thank you Dave.
Today I'd like to start off with one of the four pillars of our loan quality of portfolio, which are breast urogenital blood, Kansas and precision medicine we.
We didnt urogenital posted kenzie is an area in which we have strong momentum.
Recent positive study results further strengthen our firm choice building up on the global standard of care is set by extending and underscoring our long standing commitment to the pursuit of breakthroughs that define new standards of care.
In prostate cancer I will highlight data from two phase III studies, embark and <unk> as well as early about the promising signals from our east <unk> two inhibitor.
Each of which has the potential to reach broader patient population across the treatment continuum in prostate cancer.
Final analysis from <unk> to <unk>.
Evaluating our potential blockbuster pump inhibitor <unk> in combination with extended were presented at the <unk> results showed significant and clinically meaningful improvement across the all comer population in radiographic progression free survival or PFS in men with metastatic castration, which.
In prostate cancer.
Without homologous recombination repair or H R. Gene mutation there was a 37% reduction in risk of disease progression median PFS in patients treated with Tencent and extend it was not reached at the time of analysis versus $21 nine months for placebo plus extended.
A trend in overall survival favoring toxin a post extend it was also observed though these data are immature the final always state that will be reported once the predefined number of survival events that's been reach.
Treatment with Tulsa, and an extended resulted in statistically significant improvement in overall response rates, which suggests the potential cooperative effect between the two treatments.
The U S. FDA has granted priority review for all of its MDA portal center in combo with extended implement the aesthetic castration resistant prostate cancer with a decision expected in 2003, the ongoing tele Swedish study if successful may further extend the reach of this potential blockbuster entity.
The HR deficient metastatic castration sensitive population.
We recently presented data from our phase III embarks study.
<unk> extended plus new per lead men with non metastatic hormone sensitive prostate cancer with Iris biochemical recurrence at the American Urological Association's 2000 suite and Youll lithium.
<unk> met its primary endpoint with statistical significance and cleaning clinically meaningful improvement in metastasis free survival with a 58% reduction in risk for radio graphic progression or death key secondary endpoints were met including time to PSA progression. This.
Results suggest extended the only novel hormone therapy approved for Sui disease states of prostate cancer in the U S.
The potential if approved to extend to patients in the four months sensitive or castration sensitive setting for the first time.
Next I'd like to share early data from one of our next wave candidate.
First in class and best in class <unk> inhibitor with res shorthand as 40 97 <unk>.
<unk> two is an epigenetic transcriptional repressive that frequently over expressed in prostate cancer. We believe that inhibition of usage to may provide synergistic effects in combination with extended with a potential to address unmet needs of patients with <unk> sensitive and resistant disease here our data from our.
Our ongoing phase one two study evaluating <unk> 97 in second line M. CRP C patients with prior abiraterone <unk> extended and up to one line of chemo on the left our updated data from our phase one dose escalation study showed at ESMO last year. These encouraging results should do.
Paul Antitumor activity in both extending naive and experienced patients with all extending nave patients having received the retro importantly, this suggests that the addition of our <unk> two inhibitor that has the potential to sensitize extended resistant tumors, which is an increase in clinical unmet need.
The early <unk> date, though also highly encouraging reaching eight seven months and extend experience and $17 one months and extended nine both of which are noticeably longer than historical controls for example in the control arm of the cord study or PFS for.
Extended loon was only $4 eight months in extending naive patients.
And all the cross trial comparisons cannot be made this results in combination with emerging objective response rate and PC 50 response are supportive of the contribution of our <unk> inhibitor candidate in driving these responses.
From a safety perspective, the combination was generally well tolerated with mostly grade one and two of them. The randomized phase two study in second line <unk> is ongoing with data expected early 'twenty four.
Now, we turn to the potential for near term growth across our respiratory vaccine franchise.
<unk> or our 20 valent pneumococcal conjugate vaccine is now approved for children age six weeks. So it was 17 years, we are confident in our ability to maintain leadership in the pneumococcal vaccine space with Premier 'twenty, which offers the broadest serotype coverage of any uptick minimal.
Coca Cola <unk>, helping to protect against the twin these serotypes in the vaccine.
We have strong momentum with our RSV vaccine candidates, having received a positive verbeck committee votes supporting potential approval to help combat RSV in older adults.
And Purdue for dates for all the adults and maternal indications in quick succession in the coming months.
Just last month's New England Journal Medicine published results from the two positive phase III studies.
Emerging data from the middle of this sector or this new season in the northern hemisphere in the phase III older Adult study.
Port meaningful durable vaccine efficacy, we will share the data once complete.
In the coming months, we plan to start the phase III study of the RSV vaccine candidate in Athens to 60 year olds at high risk for us and immune compromised adults 18, and over and a phase one study two to 18 year olds at high risk.
With the potential to expand broadly the reach of our vaccine candidates both to dose H eight into 660 with hybris condition as well as to <unk>.
Listen.
Our RSV flu co administration study met its primary endpoint.
Demonstrate non inferiority for world for flu strains and the Odyssey A&P strength.
This suggests doors VAT.
In Canada, if approved could be co administered with flu vaccination and add an important component of seasonal protection against respiratory pathogens. Finally, if they recently updated the EUA per hour Omicron E. A four five by Valens COVID-19 vaccine.
To enable those at high risk of severe COVID-19 illness, including the elderly and immunocompromised to partner with our health care providers to be proactive in helping them to protect themselves against COVID-19, we.
We anticipate another update from FDA in June that will provide guidance on COVID-19 vaccine strains and vaccination timing for the 2023 of fall and winter season.
Beyond vaccines Antivirals are an important component of our strategy in respiratory viruses.
Here, we see shared data for the first time from our second Gen. <unk> COVID-19 antiviral candidate.
A potent and selective <unk> to improve inhibitor that is currently in phase one.
We design. These candidates achieved clinical exposure that would have similar antiviral activity to move it but without the need for return be boosting and.
And with the potential for reduced drug interactions early.
The result from phase one dose escalation.
Are encouraging with no dose limiting safety or Tolerability findings.
Dosing achieve concentration many fold over in vitro <unk> 19.
And is therefore expected to have similar antiviral activity to pick slogan.
On the right our preliminary results from a phase one pharmacokinetic study of Midazolam drug interactions, which is a well known standup four indicating <unk> mediated drug drug interaction.
These days I assure there is a lack of such drug drug interactions, suggesting there may be no related restriction of co dosing with drugs metabolite, but soup insight based on these encouraging data we are planning to advance to phase two dose ranging study in the first half of this year.
Addition to the assets I spoke about today, we continued to make progress on the pipeline with more than 25 milestones recently achieved or anticipated through the first half.
24 <unk>.
As examples in inflammation and immunology. The FDA has approved our MDA placebo group, enabling a label expansion for adolescents with moderate to severe dermatitis.
And internal medicine sub spreads the migraine nasal spray has received FDA approval expanding on migraine facility.
Recently, the FDA Advisory Committee voted in support of Pecs living its favorable benefit risk profile. We did soon paducah date in may.
In closing we are very excited about the potentially transformative catalyst expressed across the Empire pipeline as we work with continued urgency to bring breakthrough to patients. Thank you, let me turn it over to Chris to start Q&A.
Thank you Michael.
Right.
Can you please queue up the list.
<unk>.
At least 30 minutes for Q&A.
At this time, if you would like to ask a question. Please press star and one Keith on your Touchtone phone.
You may remove yourself from the queue at any time that question Star Q.
As a reminder, we do ask that you. Please pickup your handset for optimal sound quality.
And our first question will come from Marvin Fong with.
Evercore ISI your line is open.
Okay.
Your line is open hi.
Guys apologies. Thanks for taking my question I have two here if I may 1st.
Your expectations on the cisplatin eligible in the EV 302 trial, especially because its so significant to the acquisition youre going down the track on.
And then secondly, based on my analysis.
Omar can you repeat the question Im not sure we understood the asset.
Sure on the CE Gen trial on pads of EV 302.
Theres been a huge emphasis on cohort K, which is the cisplatin ineligible. It's my question is.
In this ongoing trial also has cisplatin eligible which is two thirds of the target population. What's your expectation there because it was I felt like it was not a coincidence Aegean never showed any data disclosure from the eligible as part a.
And secondly for the guidance for the full year I noticed.
There's perhaps a $1 billion or so worth of contribution from new launches and I'm just trying to make sense of that in light of the fact that would be they're gonna be launches sort of fall of this year I realize it's important read like RSV I mab, but is it reasonable to expect a $1 billion or so so early into the launch from those thank you.
Yes. Thank you very much I'm going to wait until the second question about.
Guidance about $1 billion.
Sales in the last quarter.
So from a launch perspective, I think the two big one to look out for this year.
<unk>.
RSV adult.
And as you know it goes through the typical ACI process. The recommendation and then and then launches can be only happened well commercialization. After the publication of the MW or so if you consider all of that puts us into fourth quarter, which is when we have not 'twenty, Pete as well as wind RFP.
The adult will actually be commercialized and revenue being generated.
And so yes, we are anticipating that there could be a big bolus of revenue because first of all what do you think about <unk> that is going to be a conversion from Perth, Nossa <unk> and <unk> today has a significant market share.
In the pediatric pneumococcal, it's 80% market share so we're going to be converting those.
The account the physicians.
The inventory all of that from.
From <unk> to 'twenty and so if you look at I guess, a good analog for that would be our <unk> 'twenty adult launch well.
Was the conversion of the <unk> adult launch and there it really well today, we have over 95% market share.
And then of course, the second one is the RSV adult.
Yeah, it plugged into a <unk>.
And already established commercial infrastructure that we've built.
Around COVID-19 around have not.
The <unk> franchise the adult franchise.
It comes at a great time during the fall and the winter when vaccinations.
For full respiratory vaccines actually increases so theres a lot of reasons to believe why that fourth quarters tend to be a really big quarter for both <unk> and RP as well as our CFO .
Thank you Angela on the question about the season.
Although it should be very careful of course, we can't comment on VAT, but maybe you can make.
Make a quick comment.
<unk> speaking, yes sure.
We're just very excited about the recent approval in the first line CIS ineligible population, which Suzanne Scott.
Which is about eight to 9000 patients in the U S and we're excited to see additional data coming in the first line cisplatin eligible <unk> two study, which as you know has had surplus tambo versus platinum Gen side of it.
We can't comment any further.
As a as a <unk> study and.
Positive that would increase the eligible population by another 10 to 12000 is operating.
Operator.
Besides us but of course.
We can't comment on Michigan's programs.
Next question please.
Our next question will come from Evan Zuckerman with BMO capital markets. Your line is open.
Yeah.
Your line is open.
Okay.
Okay.
Next question.
Yes, Sir Mohit Bansal.
Alright, Alright, sorry go ahead Evan.
Oh perfect. Thanks for taking our call. This is Keith on for Kevin maybe just shifting to M&A execution.
He can give about your recent acquisitions.
And.
You've done a great job, describing the plans to add value.
Drive commercial and clinical synergies.
We're seeing the outcomes on our end could you comment on how this is going from year end.
And then could you talk about specifics for operationalize ing the same for CGM integration and how this would differ from recent examples.
That'd be great. Thank you.
Again Angela.
Sure.
So we are incredibly proud of the work that we've done with <unk>.
<unk> since the acquisition as you know in in July .
2000, 22022, we had already begun a co promote.
With with bio Haven to ensure that we were co promoting the product early and I think that has really paid off and if you really look at what has happened from a leading indicators as well as you know actual.
Today <unk> is the leading product in the oral CERP class with over 47, 5% market share. It is also the leading product when it comes to new to brand prescription share at a high of 46%. It also has the highest number of prescribers that are about 110000 prescribers in <unk>.
The percent of new <unk> prescribers.
No tech.
So I think we've demonstrated in the time that we've had in that we are able to GCI performance and drive excellent education and awareness of the product.
And we're seeing that consistent great metrics as it pertains to network and of course that the opportunity is huge right because we have the bad Japan launching later this year and we also know that.
As a whole there are over 1 billion migraine sufferers and only 18% of them are using <unk> today. So we have a great opportunity to expand.
<unk>, but specifically in med tech.
Thank you Angela.
Next brokers.
Our next question will come from Mohit Bansal with Wells Fargo. Your line is open.
Great. Thanks for taking my question, if I may ask.
Two questions here, so on European negotiation, just because there was some news this week.
Just how much can you comment on that and the real question that is that it.
I know you've been you've provided guidance into the.
Did some of that but so far as the negotiation.
Do you have any of this to the guidance as as the negotiations at finalizing that and the other question I have is more about the demand.
Demand for <unk> globally, and the vaccination sport. It seems like you are.
Assuming both back fluid and vaccination.
Utilization cleaned up in 2024 plus timeframe.
Would it be would it be bought.
<unk> demand swing up or you think it would be either as VAT.
Conditions come down probably the demand for backfill we'd would go up how do how should we think about that thank you.
Thank you and maybe I can answer those questions.
Are you in negotiations they are still ongoing so we can't comment on but.
Yes, we have included.
Go for it included our estimation of the properties I would say is it will end up.
Yes.
We are.
So I can make any comments on that.
It wouldn't be appropriate as the discussions are still ongoing.
The demand for parts globally Tau for vaccines.
We expect that the demand for vaccines.
<unk> will go down we gave our estimations.
But we'll go down to approximately 94% of people in the U S and relevant numbers are different country by country.
As underlying demand but for boosters.
Things I think are progressing.
Progressing towards our goal we will have to see.
As most of the reasonable happened in the last.
After summer when these additional theater that through.
Also a reconciliation of our company.
Demand for quite slow right mouse following very very.
Accurately.
Infection rates so.
So when we monitor it on a weekly basis.
It is growing.
Almost equal percentage of infections is equal.
Corporate centers for British brought with them. So we expect that will continue going like you bought them.
Because we have a less compliance with national recommendations across the world as people are tired.
Corvid.
Expect a few of our people as I said this year, we'd get the vaccine Colbert.
Yeah. So this means that the protection of the collection will go down.
As a result, we expect that we will have more infections, but will drive more.
Usually quite slowly but of course, what are logical models are telling us we'll have to see what eventually will happen in the rollout.
For your question maybe go to the next question. Please.
Next we have Robin Carnesi this with Truest Securities. Your line is open.
Hi, Thanks for taking my question, just two big picture ones I'm, just first on <unk>.
For your vaccine franchise, as we think about the competitive landscape.
A couple of things what do you think is maybe the most important differentiation for you versus the competition and that will drive the most uptake as people have different options.
And have you developed any new LNP technology that might reduce the biggest pushback with the vaccines as people sell nextel when they've got them for some of your products.
And then lastly, just Swedish kroner also.
Which product you you spoke about.
I'm just talking about the Frac vaccine franchise for RSV and flu like Covid thinking Big picture. How you are differentiated and what do you think is going to be key because you're all competing to make.
Herman who is going to be the winner.
And then second question in terms of the MRI <unk>.
Polls will out of Europe .
For hurting.
Heard any legislation heard rods and since you're launching new products in Europe I just wanted to get your thoughts on whether or not you think that legislation may hold or what kind of impact that might have.
Thank you.
Maybe I can give you a very general answer, but my friends and loved ones too.
Ooh concern me.
On the corporate.
Right right.
The big markets there.
Uh huh.
We plan to maintain them. So I think we are there.
When it comes to RSV.
We are the only ones, but we have both.
Oh.
We have positive data on both on adults and.
No.
We have already approved for adults and then we are.
We're expecting approval for apparel so about.
The strength of all our data with efficacy and safety profile that we've seen.
Yeah.
We will provide us with.
What we hope also to be the winners and that's what are they for more.
On Mris spillage are resolved we are already domestic with the totality of the data book that are having promo flu vaccine.
We will await to see of course.
We continue and then of course, the warehouse will be.
We also thought they would be able to replace all of them. So the fact that we have all three of them or we have it goes across all three of them started this our successful N V for the projects that are proof of course social provides good pronunciation.
But I think the trusted advisor brand name with CRISPR.
Been a very very strong.
I think also for various a key.
No.
You legislation, but appreciate it.
Comparison base.
We are we are not.
I'll be seeing.
The positive things for you trying to be more competitive.
Sure.
And that creating a regulatory framework for more rafi approvals.
We are also concerned at the same time with provisions.
We'd like to reduce.
Oh data.
Uh huh.
Appropriately so.
We hope that there will be an open dialogue with the U S. So about the <unk>.
We can create the framework, but really will end consumer base.
Until or anything, but you want to add to all of them.
Maybe just to add to your question specifically about the adult portfolio.
I really do believe that this plays into our sweet spot.
Through the last several years both from the <unk>.
<unk> franchise.
Nathan Vaccinating adult throughout Western Covid, we've learned that the clinical profile is one thing, but you really need reliable supply you need a commercial infrastructure you need a great ability to educate raise awareness and drive people to vaccination and then I think on all of those counts.
Pfizer is the winter and so we look forward to having a growing in a very robust respiratory portfolio that really leverages topped off this incredible commercial machine.
Thank you next question please.
Next we have Louise Chen with Cantor Your line is open.
Hi, Thank you for taking my question so wanted.
To ask you about margin improvement you talked about that in your opening remarks, I'm curious when we might start to see that and does that include the CE Gen acquisition in your comments and second question I had for you is what are some of the key steps that you've taken already to transition come or not impactful to the commercial markets.
And when will you know how the season will shape out thank you.
Thank you very much Louise.
David do you want to take the marketing improvements and then I'm done.
Yes. Thank you for your question. It is our expectation that as we integrate CGM in either late 'twenty three or 'twenty four early 'twenty four we will begin to see margin improvement and that will happen as we continue to improve our performance from a top line perspective at the same time, we're gonna be very a fish.
And really work to minimize our investments going forward. So I think you should start to see that post the integration.
And the closing of the <unk> transactions.
Thank you David.
How are we preparing to transition commercial requirement.
So Luisa you know both of these products both commodity FX loaded.
Our products are very familiar to us they fit very well in the existing portfolio of products that we have.
So the ability for us to move from an EUA into a full launch or is it business as usual for US right. So the typical things that we would always do which is awareness building with physicians and with patients.
It has begun and is well underway.
Things that you would do as ever thought.
Well discussions with payers to demonstrate value.
And to create your value argument for reimbursement and access that has begun.
We have done a tremendous amount of work as it pertains to retailers and making sure that we have our distribution and our supply chain you know well.
Well oiled and the ability to be able to supply in Quebec to NATO administer these products at both at the physical side like a retailer or even in the case of Opex low bid getting telehealth and instead of remote health remote health capability set up.
So all of these capabilities and many of them in fact I've been underway throughout.
The entire time of the pandemic. So I think we're in very very good position to assume the fee transition into commercialization.
Thank you Angela next question please.
Our next question will come from <unk> with Jefferies. Your line is open.
Hey, Thanks, so much can you talk about your Nextgen CDK four program, you'll have first in human data at <unk>. What is your team believes jet hitting CDK four allows you to improve on <unk> efficacy.
And are there any plans to combine that drug with the our venous third given the DDI that's been shown up with <unk> and then on your next Gen. <unk> program can you confirm that it can achieve multiple fold over the EC 90, when adjusted for plasma protein binding and is that for timelines on that product.
The earliest possible commercial entering 2026 or is there a path for expedited approval. Thank you.
Thank you very much micro I think both questions can go thank you.
Very excited about the Nextgen CDK <unk> inhibitor, it's looking really good and two aspects you can dose and get the activity after patients pay the CDK four six because you deal with with how Youre inhibition of this mechanism.
And you.
Had a better tool ability.
No with much less neutropenia less risk for infections.
We expect a midyear report out and we have.
And aspirational target to start phase III.
This year posted earlier at the same time as you all as we are now running combination studies to care for with Cat six.
And another.
Inhibitor that has a nice senior agent activity and seem to combine well we have a second combination with CDK too and we think this would allow us next year too.
Pick one or two combinations to advance up the lines with more potent treatment that whats available today. Similarly, we're looking at combination with $4 seven one as you alluded to in order to benefit from <unk> collaborations.
Collaboration next Gen Tech slowly yes.
Alluded to in my introductory remarks, we have many fold above 90, and as you know for peg slowly and what's unique with a drug that the medical exposure above USD 90, as these four lead to no detectable meaningful the emergence of mutations.
Which is always what you see here, an antiviral senior agents a therapy and he's just been unique <unk> versus other agents that have been used to for whether antibodies or antivirals.
And this is exactly the profile for the next gen, but without <unk> that allow us to improve and also to move into other supplementary segment.
We are planning soon to start.
Two.
Pending data.
Possibly move quickly to phase III and of course, we would like to see that the agent introduced as soon as possible I think we can.
Hoped to move swiftly pending.
Event rates of Covid that will happen in the fall and further on that influence enrollment.
So I think you said 26 and I would certainly hope we will be ahead of that thanks.
Thank you goodbye.
The next question please.
Next we have Karen Flynn with Morgan Stanley Your line is open.
Hi, Thanks, so much for taking the questions maybe two for me because I'm not sure you'll be able to answer one of them I guess any.
I would love your latest thoughts on your seasonal flu mrna vaccine.
Just in light of some of the midterm the data on the B antigen side. Just you know how should we think about your profile. There and then there's been some focus on this et cetera versus Opdivo first line Hodgkin's lymphoma data.
On a per presented at <unk> just wondering if you can offer your high level perspective on how you see that our frontline landscape evolving. Thank you.
Thank you Michael why don't you take the crude question and then Carlos Your question will go to William.
You know we are very pleased what we see so far the totality of data of our flu mrna.
As you know we have reports about very high antibodies.
A similar or possibly lower to the b M against versus standard flu vaccine, but in contrast to standard flu vaccines, we have very nice T cell activity and I think we are the only mrna platform that has those CD four and CDA T cells of significance, we do think that could offer you.
<unk> profile for flu.
And the Tolerability with Idose.
Very encouraging so the trial is in the last leg for a readout hopefully we'll be able to late to this forward to chevron upstate than we are.
Very encouraged and we are in parallel with investing in the combination.
Opportunities with some COVID-19 in RSV in various combination as Albert already alluded too. Thank you have a microphone William on the oncology front.
Yes sure. So again this is a molecule for <unk>.
Which is the CD 30 ADC.
As already been approved in Hodgkin's lymphoma post transplant and then in previously untreated Hodgkin's lymphoma now with chemotherapy.
We've assumed in Boston and Dacarbazine.
And it's already we anticipate actually later this year that the label will be updated for overall survival and.
Now the data you're talking about it from the swap S. 18, 26 study with Evo Abd versus et cetera, et cetera, It's abd and I believe there'll be presenting PFS data, but this is a terrible disease and we believe that the update with the Texas label will show that etc is the favorite.
At this time.
Thank you.
Next question please.
Our next question will come from Colin Bristow with UBS. Your line is open.
Hey, good morning, and thanks for taking the questions.
Maybe first.
Then you get pulled in the upcoming data could you just walk us through what the key efficacy and safety thresholds you are looking to meet to move this forward.
Yeah.
With regards to those thresholds, how you think about that.
I'd dosing and how does that potentially impact, but sort of commercial opportunity.
And then just second a quick quote I know DMD phase III separately trawl you previously guided to completion of recruitment in April of this year, just could you give us a quick update here and then how you view the opportunity and positioning in light of the fact that as a potential competitor approval at the end of this month. Thank you.
Michael Yeah, you know we are very excited about our two or at least the $50 32, and then we'll get to 15 substitute called <unk> and we're looking for a differentiated profile that will be a combination of.
Rapid onset.
Hi control of <unk>.
HBA <unk>, bringing it down and body weight loss at those doses to be very competitive and more easily tight for both drugs that can optimize our preferred profile versus injectable when it comes to nausea, and other well known when you think.
So we look forward very much to our data maybe later this year or possibly early next year and Cherry pick. The we knew you you also asked about the M D.
Well if the approval is based just on the surrogate markers and indeed I think it's very important.
To and report out data when it comes to real patient benefit and we.
We expect.
Possibly already late this year.
Turning to the next year to have data from the first randomized study.
If positive could show favorable benefits for patients doing better according to the North star.
Our scale. So we feel really positive about our own DMD program and I think the industry will be competitive with the real data that patients need.
Thank you Michael next question please.
Our next question will come from Jeff Lee Chen with Bank of America. Your line is open.
Hey, guys.
Thanks, so much for the question.
Just have two.
First Angela on the Ini landscape can you just talk about your expectations for category growth just looking at this year and next just in light of the Humira and still are a biosimilar to come I'm asking just in the context for the <unk> launch as well as our Sabine quote and then Albert I know this question.
<unk> been asked.
Different way, though I know you expect this year for COVID-19 to be a down year, but when you think about your scorecard outside the U S with payors as you've transitioned to commercial.
What's been the initial feedback from sort of from a price and volume perspective, obviously, that's key to your assumptions in 2024 and beyond thank you.
Let me answer with a corporate question and then Angela will answer.
Right.
Unscathed.
We expect to have a commercialization.
In the U S I think likely.
Likely the year's government stopped purchasing outside the normal time.
We do not expect that to be the case in most of the competition, but we think that's where most of the competition will continue.
Or have any governmental practices.
Most of them would have already long term contracts. So I don't think there will be months penetration of our VAT in the price or.
Given their longevity of the product from the products the contracts expire Crestwood price disruption would be adjusted.
Let's move to the question about IMI and I'm deliveries.
Well I think to answer that question you really have to look at each each product in the cat and the specific disease, that's that they're in so let's start with <unk>, which as you see.
They are we believe that we haven't yet we have an advantage on the clinical profile perspective, we believe that we have the best in class <unk> inhibitor, but there are also other great benefits such as the fact that it can be used steroids suite that we have convenient dosing.
We also offer an oral option.
World that is a that is a very prevalent with injectables.
And even with all of that that's out there we still have 50% of people that have not achieved submission. So I think that the unmet need and you see it is clear.
And for US in particular, given the profile of <unk>. What we think is the greatest opportunity for US is in earlier lines of treatment with it has not been as much advancement right. There's a lot of anti TNF. There's a lot of Biosimilars is Jeff there's other mechanism, but in earlier lines of treatment. They really is not.
In the us and so that's where we think we have an opportunity to meet him and underserved needs today, and that's where I was going to be.
Where are we going to be positioning.
It has them on it.
<unk> is a different story.
When you look at that particular indication for alopecia that is really an underdeveloped market. There's 3 million people today than no great option for adult and there are absolutely no option for for adolescents and children and so the profile that we have witnessed at Nab is a it's the best in class Jack the best Jack.
And I think that we're going to compete well. In addition to the fact that we're going to be the only JAK compared kibera fitness that has an invitation fallout for adolescence. So I think in this regard because it's a new Disney eat on a highly undeserved disease, I think education and awareness education at the level of prescribe the patient, but also with the payers.
It is going to be key to our ability to access that market.
And of course, assuming resolve itself.
Okay.
Next question please.
Our next question comes from Trung Nguyen with Credit Suisse. Your line is open.
Hi, guys morning, Trung Nguyen from credit Suisse I have two if I can so first one a few days ago you saw the FDA Advisory committee vote on limb pauses propel trial.
In that the committee voted against the approval in all comers.
For 2000, and the counterparty to what's your expectations for your label here given the strength of your data and could that affect your $1 billion peak sales number that you gave in December .
And therefore, the RSV flu co administration study what flu vaccine did you test that with is that the high dose for the low dose and if it's the low dose could you be approved for use with the high dose which is more relevant today. Thanks.
Thanks very much.
Yeah.
Thank you very much William would you like to take the collateral part of your question Yeah sure. So thanks for the question. So as Michael said the study showed a with Nvidia plus cell approach 10, tele versus and we showed a 37% reduction in the radiographic progression free survival.
Notably the same presentation. We also show the hazard ratio in the HR deficient population of four eight a significant P value and then the HR non deficient unknown population.
0.7, with a P value of 0.0 for it so.
So we remain confident about our data in the all comer population, obviously, we can't compare to propel notably in telephone too we have prospective testing for HR.
Deficiencies, including the RSA I wanted to I also want to point out that our control arm of extend you reaffirmed <unk> Andy is the best in class a and.
H T or for the indication with the radiographic PFS of 22 months.
And then the.
Keeping our metallic PFS was not reached.
So we expect that the HR population, which is 25% will.
B are compelling with the data.
And we will also continue to present additional data in the HR subpopulation of Astro in 2023, and notably we did get priority review and we're currently in registration.
Thank you William and micro wasn't bulk RSV.
Yeah. You know we are extremely excited about the RSV vaccine and we will provide data on co administration of that vaccine with our adjuvant flu, we expect it to be.
Available and generalized to all flu vaccines.
And.
Then when it comes to.
Longer term, we also already.
In the combination study with our RSV.
Using our internal portfolio of Covid and mrna flu. So we see this as an event developing a very strong portfolio of DCA with co administration opportunity is next.
Next year, possibly our own flu vaccine and then combination thereof, so stay tuned.
Thank you Michael.
Next question please.
Our next question will come from Andrew Baum with Citi. Your line is open.
Thank you just coming back to the U R. G. L. P. One portfolio.
Lilly has.
Call that an anticipated weight loss sets such two weeks from memory of around 14% to 15%.
I hesitate to give baseline given the competitive nature of the field.
Your late to market.
The cost of running cbot.
Trials in this setting.
Where does the relative weight loss needs to be from your phase two for you to advance given the benchmark that Lilly seems to be setting.
Okay.
That's a good question for Marco market, Yeah, No we agree completely with you that the.
We should have an ambitious profile and we have certainly seen in patients up to 15% weight loss, depending on different dose regimens. So.
<unk>, that's a really good ambition to have up to 15%.
And.
Would there be some patients of course, it's about having a very strong HBA when CLO.
Maybe 2% or even more so we think it's feasible with all roads and we think that will open up a very large place and we think that.
Pending data readout.
We may have a differentiated profile for our food aggregators.
Thank you Michael So we are we are waiting to see the data that would speak.
Let's go to the next question please.
Next we have Chris Schott with Jpmorgan. Your line is open.
Great. Thanks, very much just two questions for me maybe first one on the capital allocation comments I guess, the more balanced capital allocation post the.
S. Gen Delevering.
On that front, where do we need to see leverage go to before we can think about that balanced allocation and in the meantime.
What is the capacity and appetite for further deals. So can we think about kind of bio haven size deals, while you're delevering from sea Gen or is it really smaller transactions.
And then my second question was just a one on RSV market development.
Quickly do you see this market developing I guess I'm, just trying to get my hands around how much education disc require and do you worry at all about vaccine fatigue, I guess, just given all the boosters that this population I guess received during the pandemic does that slow at all of the uptake versus kind of a normalized environment. Thank you.
Good question I'm curious are they kept all of our case, yes. So.
Thank you Chris for the question, obviously, we have invested heavily back into our business.
Here's all with the focus of growing our business from both from a top line perspective, but importantly from a bottomline perspective, and I think now as we begin to cycle into <unk>.
I'll say post the peak of this reinvestment in the business. We should begin to harvest. If you will some of the cash flows coming out of the investments that we made in capitalized if you will on the returns that we expect out of these investments so having said that.
We expect because of that we should get ourselves back more balance into the three pillars again reinvesting back into our business growing our dividend and doing a value enhancing share repurchases.
From a leverage perspective, obviously, we want to maintain our high investment grade rating and access to tier one commercial paper that would say that we would probably be in the low three times Levered zip.
ZIP code from that perspective.
And then from a M&A perspective, we're still active in the M&A market, obviously first and foremost on our objective now is to close and begin to integrate CGM. So that's priority number one.
Having said that we will still look at the M&A marketplace understand if there's assets that meet our criteria to supplement our business and we could theoretically execute against that given our capital structure, having said that in the near term. That's those will probably be smaller little tuck in type deals given.
Our leverage ratio in the very near term.
Thank you.
Okay got it.
The educational effort with the market.
Well with all launches education is really important and and that's why we've already begun our unbranded disease education with physicians on laying the groundwork for the importance of Vaccinating with Oh, Vaccinating for RSV, and but of course with all launches and with all of you know all new diseases and.
Education important too to consumers, it's important to caregivers to payers and so on all of those fronts and those discussions have either the gun or all beginning and we plan to obviously implement a robust market development plan like we do all of our vaccines.
I think that's the biggest advantage here is in the synergies of RSV together with all other adult vaccine we have have not 20 adult.
Covid, we you know all of these vaccines, although a very similar pattern in terms of.
The commercial needs.
That they have and I think that we have the opportunity to quickly and seamlessly bring RSV on into our portfolio and use.
The very same approaches mechanisms in the same conversations that were with us with a retailer whether it's <unk>, whether it's with.
All of our points of vaccination to bring occupying RSV.
So actually I think that this is a very exciting time and we feel very confident about the ability to seamlessly seamlessly introduced RSV as another another vaccine in our respiratory portfolio.
Thank you next question please.
Our next question comes from David Risinger with SBB Securities. Your line is open.
Yes, thanks, very much first could you discuss the pack slow bid private market sales potential in China.
After March 31st that isn't included in your <unk> guidance for the year and also could you comment on the late stage competitive threats from Santa fees 21, valent pneumococcal conjugate vaccine in adults and infants and Merck's 21, Balan and adults. Thank you.
Thank you Angela.
Angela scrub it quickly.
Private market and so I'm sure. So after April .
We are we continue to have tax low that available and but it will be accessed through and out of pocket payment mechanism. So if you're a private patients you can get it if you're a public patients you can get it you just need to be able to pay out of pocket for it and and we intend to continue to watch.
With with the public and with the Chinese government changed with that.
Now guidance for a particular product in a particular country so but.
I'm going to explain the dynamics of micro very quickly remember competition or new corpora, yes, I mean, we are.
Seemed excited about the PCB twin the recent pet rescue approval with the stellar label, reflecting the strength of our data.
We monitor it carefully competitor activity as you alluded to.
Our planning ourselves to enter next year.
Further expanded piece V vaccines.
Bye.
Additional expansion a few years later, including optimization of the congregation procedures.
Including a different carriers and possibly for the adults also add your events that we think could be useful. So this is a market where we have been the leaders we have a unique platform and we monitor and.
Feel very confident that we are going to have a bright future. Although you mentioned competitor, which is the nature of markets that are becoming of course are more saturated we'd like the adult market, but there were also hope to benefit from our broader portfolio.
Respiratory vaccines from cold with flu RSV that cannot be matched by others at the moment. Thank you. Michael next question. Please.
Our next question will come from Steve Scala with Cowen Your line is open.
Thank you I have two follow ups first on pneumococcal vaccine. So Pfizer just started a study of <unk>.
A vaccine, including a new ingredient is the new ingredients in adjuvant is it more valence or is it something else.
And then a follow up on the Opdivo versus etcetera study can you say, whether you were aware of the data at the time of announcing the <unk> acquisition and why should we not view this as a significant risk. Thank you.
Thank you micro workers this at group ingredients.
[laughter].
You know that in <unk>.
Secret sauce in this particular trial is the new adjuvant that we think could play in.
And potential <unk>.
<unk> role in the PCB market as you go to increasing valency in this space.
As I've said before.
Parallel we are working on.
Looking at the a friend carriers different chemistries.
And we'll let short reveal for next year start of AR.
Our broader expanded PCV vaccine.
We will cooperate all these learnings so stay tune and William on the again on the Opdivo stopping yeah sure. So again on the Opdivo study. That's locked study has been ongoing for a while we were not aware of the data that's going to be presented at Astro.
I would reiterate again, it's early PFS data from what we see and the most important.
A measure of activity in Hodgkin's lymphoma would be overall survival and again, we expect CE Gen to get an updated label.
<unk> overall survival benefit in first line Hodgkin lymphoma.
Thank you next question please.
Our next question will come from Kerry Holford with Aaron Berg Your line is open.
Thank you very much.
On the Rx team.
Inc.
Older adult vaccine.
On slide 22.
Okay.
Unfortunately channels.
I'm wondering if you can elaborate a little more at <unk>.
One can continue.
Hey.
And you wanted to add that.
Pedro.
Okay.
I can see how.
How my opinion.
EMEA.
And I can really only maternal vaccine.
Pat.
Turning to the full.
Six.
The same time.
At quarter end.
Yeah.
And could you just have more clarity on winter.
I kind of a vaccine.
Sure.
Sure.
Micro or the bulk of the Odyssey works, Yeah, we were very pleased to get the.
Our first data Sean from second season, we'd see some data.
For older adults and it clearly shows that.
Robust date that we shed for example, we shed.
Hi, 80%.
Reduction in low respiratory tract infections with the suites.
So he symptoms we see also on this and similar on other endpoints are very robust very meaningful protection all seen the second season.
Now as you know at the same time, we are preparing for the future combination vaccines.
We think in general that you will see an evolution in the adult market with simplified vaccination schedule.
<unk> explanation of Covid flu RSV.
For those that for some reason midst of explanation. We think the second season of data will be very good.
On the maternal.
Are preparing for an advisory committee, we think we have great data. We are the only one that had been able to conclude the maternal vaccination with.
We had only one that were able to construct an RSV vaccine without using an adjuvant.
And we think it's a differentiated product and.
I assume will be.
Soon after potential approval.
And the opportunity for Angola to launch to very eagerly await and community.
Increasingly attentive.
Pregnant women and maternal clinics to protect the newborn alright. Thank you Mike as we've set them out.
In our slides, we expect to be approved.
In this year in the last quarter or so launch we expect the publication of the M. W are likely to happen beginning over the next year. So that plays all sorts of Eric you're already in the uptake of the vaccine, but keep in mind that loans were purchased before the approval right. We spent a lot of our traditional levels and there are a lot of investments that we are doing in Brookfield.
In that aspect of the launch of <unk> has stopped from outside expertise.
Next question please.
Our next question will come from Carter Gould with Barclays. Your line is open.
Great. Thank you for taking the questions I guess first on the decision to establish a new operating segment and specifically launched this Pfizer ignite offering can you talk about what drove that and if there's sort of like an aspirational target and how meaningful of a driver that could be and then secondly sort of on the decision to divest but NCO did.
Does that reflect a sort of a signal you've got some FTC or proactive move in your in your mind or are there. Other factors, we should think about and the fact that we haven't seen other divestments to that sure.
Reinforce our confidence that do you think the deal can go through without other issues. Thank you.
Okay. Thank you very much on the province your question.
The discussions to return to their rights or.
For royalties.
For royalties could started well before.
Season, So it's nothing to do with.
The original Susan was something that was ongoing between us and Mexico runoff or the benefit of the product and enforce the British citizens.
Exhaust the was completed after we announced the deal shortly thereafter.
It started way way before.
Sure Amit.
Amit would you like are supposed to explain.
The ignite business, yes. Thanks for the question I think you've seen us collaborate with the biotech ecosystem in lots of different ways and Pfizer ignite.
Either way in which we can effectively do that frankly, there's a lot of interest and demand on the part of particularly by effects for working with us to access some of our distinctive research and clinical development capabilities and we think it gives us a platform to do that to work with these companies get closer to the science.
Which over time also then improves our ability to access that science and make determinations about what we would like to bring in house. So we think this is a.
Excellent way for us to continue to collaborate with biotech ecosystem and add to our growing and compelling pipeline over time.
Your.
Next question please.
Our next question will come from Chris <unk> with Goldman Sachs. Your line is open.
Thank you on taxable event the U S commercial opportunity can you update us on any framing of what youre thinking in terms of pricing and when we would know that and in particular with the commercial availability are you anticipating much in the way of sort of payer engagements in terms.
Thinking about how that process will unfold utilization management mice.
And then on the business development front.
We go to the $30 billion that you had outlined for a while now and think about what is remaining from that on adjusted target in terms of 2030 revenues, let's say approximately $5 billion is left.
We're thinking about how you guys are contemplating what areas to go into in terms of verticals or therapeutic areas or modalities would it be fair to expect that at this stage.
A consideration might be to minimize the extent that you would have to rebuild or sort of refurbish on ESI and aim front given your margin objectives longer term. Thank you.
Thank you Angela on in park slope, if the commercialization sure.
So hi, Chris Yes, we're preparing for launch now, but as we've said.
As we've shared before that.
The date of knowledge and exactly how that's going to happen is I'm still very much subject to our discussions with the U S government. So it wasn't in line with you know.
With that with guidance from them in terms of how that's going to happen.
Of course in the meantime, we are preparing for the commercialization opex, a little bit and payer discussions around the world is critical so that those have begun obviously too early for me to share the price opex, a little bit, but suffice to say that the price ranges that we have brought to our payers together with the value arguments.
That we have been able to develop through robust real world evidence from the number of hospitalizations and number of deaths that we've been able to thread through the treatment with <unk> is a very much supportive of the pricing changes that we're talking about thank you Alethia I think very soon we'll be able to sample and me.
About what is the profile of <unk>.
Yes.
Yes, Chris as you mentioned, we have a goal of 25 billion and risk adjusted revenue by 2030.
We should remind everyone that as a 2030 goal.
We with the deals that we've done have a remaining balance of less than 5 billion against that goal and I think our strategy to pursue that it's going to be consistent with what we have employed to date now first and foremost it's going to be about compelling science that we can add value to.
And it's also going to contribute growth in the 25% to 30 30 to take lots of things into consideration, including the impact on the P&L profile. So that will continue to be our focus and will continue to be disciplined in the opportunities that we look for it and as Steve mentioned earlier, our priority right now is ensuring that we closed out.
And successfully integrate the CGP transaction as well as drive value from the other deals that we've done and will continue to actively look for opportunities.
Thank you Ms. We ought to be felt at the time. So last question. Please.
Our last question will come from Tim Anderson with Wolfe Research. Your line is open.
Thank you.
Couple of questions. The first is how much of your future Covid vaccine revenue forecast are tied to the ability to have a combination product if something like mrna fluid ends up not being viable and a knockout of flu COVID-19 combo does that could that impact.
Impact your anticipated uptake in 2025 and beyond or can you get to those longer term guidance levels.
Regardless of whether you have any combos or not and then last question Albert I am guessing there was some frustration among.
Among management and what the stock's been doing a tough 2023 2022 wasn't a great year.
Despite pfizer, helping lead the world out of the pandemic, which was a remarkable accomplishment. Even today you beat consensus stock is down a little bit so as you talk to analysts and investors.
Are you hearing or the biggest concern is that you think could explain this and what do you think analysts investors are missing or misunderstanding.
Thank you. Thank you Tim let me start with the first one we do expect that.
But our successful combination with Peru, but will drive the organization of our corporate purchasing much higher ASP.
You normally know rescue medicine should be expect for example in the U S. Around 24, 25% in the next few years, Oh for the vaccine, but Peru.
Right now utilization around safety. So there is a big gap.
So that's why we believe they can be matched between flu and COVID-19.
Will arise also the carpet and the Venezuelan.
Well that's all we can go all the way up through the same utilization like.
Like flu, particularly given that there are no codebase and approved.
Recommended vaccines.
As regards the frustration.
For the <unk> 23.
I believe that the stock price right now does not reflect the value of that.
Hi, Faiza credits.
The fact that.
We are still broad because of our contributions settling the warrants type of thing.
We expect.
Stock price increases because of what we.
We did it because it was the right thing to do and I think we are very very powerful.
Expect to see stock price increases as we are executing our plan, which is to create sustainable top line revenue growth.
But that will allow us to leverage the bottom line.
We will grow faster than the top line.
I think we articulated the plot about block by block was too.
Investing in or acquiring.
Good scientific substrate, but will allow us to launch products that will give US 95 billion revenues by year three MDA start there and to have done tremendous progress on like having already according to our calculations Randy.
We are also investing in R&D and the less the or in the car.
Last two years and we have now an unprecedented.
Or for new programs.
And I think.
He is expecting to see how those launches what level.
Clearly I think there is overtime.
Over a coffee forever.
Uh huh.
Uncertainty.
Corporate revenues will be materialized, we don't have any.
Presidents to two so that we know are hard to predict as well. So all producers are faced.
There are some logical science and based on the primes with drug testing with the.
Market people. So are you seeing that.
From my perspective, what I said was our phone because of your vertical.
Creating violence orders are August we know that everything we do we do it with.
And Mike you spoke of a moment.
We want to be very good stewards soapbox Smoky mountain. Besides the world I think also when you introduced or surprised and grow.
Committed to do that by explaining Petrobras Roberts and more importantly execute on it.
So we got I think gave me also a theme of goods.
Segue to close.
Summary, we believe.
Sure.
That was a solid quarter, we deliver.
Oh, no commitments, we execute actual expectations, we know from history.
We will continue doing so.
The campus, but we would agree cereals volume for patients.
Got you a survey work translate into value for stockholders, we are executing our plan.
We remain very committed to doing that thank you very much to all.
Have a nice day.
Yes.
Thank you ladies and gentlemen, this does conclude today's teleconference and we appreciate your participation.
You may disconnect at anytime and have a wonderful day.
[music].
[music].
Yeah.
[music].
[music].
Okay.
Uh-huh Oh.
Hum.
[music].
Okay.
[music].
Uh huh.
[music].
Sure.
[music].